2016
DOI: 10.2169/internalmedicine.55.5980
|View full text |Cite
|
Sign up to set email alerts
|

Autoimmune Hemolytic Anemia Induced by Adalimumab

Abstract: The Authors Reply We would like to thank Dr. Nagashima and colleagues for their interest in our recent article (1). We agree that care must be taken when assessing the causality of uncommon drug-induced adverse reactions, which was mentioned as a potential limitation in our study (1). However, although Garratty stated that typical drug-induced autoimmune hemolytic anemia (AIHA) occurs soon after the administration of the drug (2), delayed-onset drug-induced AIHA cases that occur 24-60 months after cladribine a… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2022
2022
2022
2022

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(1 citation statement)
references
References 3 publications
0
1
0
Order By: Relevance
“…Certain therapies used in the treatment of IBD are an additional factor that can cause anaemia. These include 5-sulfasalazine derivatives (20) , azathioprine (21) , cyclosporine (22) , infliximab (23) , and adalimumab (24) . Therefore, blood cell counts should be monitored periodically during treatment with these agents.…”
Section: Inflammatory Bowel Diseasesmentioning
confidence: 99%
“…Certain therapies used in the treatment of IBD are an additional factor that can cause anaemia. These include 5-sulfasalazine derivatives (20) , azathioprine (21) , cyclosporine (22) , infliximab (23) , and adalimumab (24) . Therefore, blood cell counts should be monitored periodically during treatment with these agents.…”
Section: Inflammatory Bowel Diseasesmentioning
confidence: 99%